A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer

doi:10.3389/fimmu.2021.778276

	A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
	Peng, Jie 1,2; Zou, Dan 2; Han, Lijie 3; Yin, Zuomin 1; Hu, Xiao 1
刊名	FRONTIERS IN IMMUNOLOGY
	2021-12-15
卷号	12
关键词	non-small cell lung cancer support vector machine major pathological response liquid immune profiling neoadjuvant treatment
ISSN号	1664-3224
DOI	10.3389/fimmu.2021.778276
通讯作者	Peng, Jie(sank44@sina.com)
英文摘要	The biomarkers for the pathological response of neoadjuvant chemotherapy plus anti-programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) (CAPD) are unclear in non-small cell lung cancer (NSCLC). Two hundred and eleven patients with stage Ib-IIIa NSCLC undergoing CAPD prior to surgical resection were enrolled, and 11 immune cell subsets in peripheral blood were prospectively analyzed using multicolor flow cytometry. Immune cell subtypes were selected by recursive feature elimination and least absolute shrinkage and selection operator methods. The support vector machine (SVM) was used to build a model. Multivariate analysis for major pathological response (MPR) was also performed. Finally, five immune cell subtypes were identified and an SVM based on liquid immune profiling (LIP-SVM) was developed. The LIP-SVM model achieved high accuracies in discovery and validation sets (AUC = 0.886, 95% CI: 0.823-0.949, P < 0.001; AUC = 0.874, 95% CI: 0.791-0.958, P < 0.001, respectively). Multivariate analysis revealed that age, radiological response, and LIP-SVM were independent factors for MPR in the two sets (each P < 0.05). The integration of LIP-SVM, clinical factors, and radiological response showed significantly high accuracies for predicting MPR in discovery and validation sets (AUC = 0.951, 95% CI: 0.916-0.986, P < 0.001; AUC = 0.943, 95% CI: 0.912-0.993, P < 0.001, respectively). Based on immune cell profiling of peripheral blood, our study developed a predictive model for the MPR of patients with NSCLC undergoing CAPD treatment that can potentially guide clinical therapy.
资助项目	Qian Dong Nan Science and Technology Program[qdnkhJz2020-013] ; Science and Technology Foundation of Guizhou Province[Qian ke he ji chu-ZK 2021] ; Science and Technology Foundation of Guizhou Province[yi ban 454] ; Science and Technology Fund Project of Guizhou Provincial Health Commission[gzwjkj2019-1-077]
WOS关键词	METASTATIC NONSQUAMOUS NSCLC ; SPECIFIED FINAL ANALYSIS ; TUMOR MUTATIONAL BURDEN ; PEMBROLIZUMAB ; PLATINUM ; LYMPHOCYTES ; EXPRESSION ; EFFICACY
WOS研究方向	Immunology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000738681800001
资助机构	Qian Dong Nan Science and Technology Program ; Science and Technology Foundation of Guizhou Province ; Science and Technology Fund Project of Guizhou Provincial Health Commission
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/127205]
专题	中国科学院合肥物质科学研究院
通讯作者	Peng, Jie
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China 2.Guizhou Med Univ, Affiliated Hosp 2, Dept Oncol, Kaili, Peoples R China 3.Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
推荐引用方式 GB/T 7714	Peng, Jie,Zou, Dan,Han, Lijie,et al. A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer[J]. FRONTIERS IN IMMUNOLOGY,2021,12.
APA	Peng, Jie,Zou, Dan,Han, Lijie,Yin, Zuomin,&Hu, Xiao.(2021).A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.FRONTIERS IN IMMUNOLOGY,12.
MLA	Peng, Jie,et al."A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer".FRONTIERS IN IMMUNOLOGY 12(2021).